Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a cold virus drug ease COPD Flare-Ups? new trial results are in

NCT ID NCT06149494

First seen Oct 31, 2025 · Last updated Jun 15, 2026 · Updated 37 times

Summary

This study tested whether vapendavir, an experimental antiviral drug, could reduce lower respiratory symptoms (like cough, wheezing, and shortness of breath) in 52 adults with COPD who were deliberately exposed to a common cold virus (rhinovirus). The goal was to see if the drug could prevent or lessen the severity of COPD flare-ups triggered by the virus. The trial has been completed, and the results will show how well vapendavir worked compared to a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU)

    London, W2 1NY, United Kingdom

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease common cold enterovirus infectious disease Infections infectious disease lung disorder obstructive lung disease pulmonary emphysema Respiration Disorders respiratory system disorder respiratory tract infectious disorder RNA Virus Infections viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.